Broker sees upside in Lumos Diagnostics after key regulatory milestone

Foster Stockbroking has increased its target price for Lumos Diagnostics from 42 cents to 51 saying CLIA waiver for FebriDX ... Read More The post Broker sees upside in Lumos Diagnostics after key regulatory milestone appeared first on Stockhead .

Go to News Site